Analysts Set Expectations for Neurocrine Biosciences, Inc.’s Q1 2025 Earnings (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Neurocrine Biosciences in a research note issued on Tuesday, April 23rd. William Blair analyst M. Minter anticipates that the company will earn $1.28 per share for the quarter. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.84 per share. William Blair also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.56 EPS, Q3 2025 earnings at $1.75 EPS and Q4 2025 earnings at $1.99 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company’s quarterly revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.88 earnings per share.

Other equities research analysts have also recently issued research reports about the stock. Wedbush reiterated an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of Neurocrine Biosciences in a report on Wednesday. Barclays upped their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Tuesday. Finally, The Goldman Sachs Group boosted their target price on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $142.38.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $137.76 on Thursday. The firm has a market cap of $13.71 billion, a P/E ratio of 56.93 and a beta of 0.25. Neurocrine Biosciences has a fifty-two week low of $89.04 and a fifty-two week high of $148.37. The firm has a 50-day simple moving average of $136.56 and a two-hundred day simple moving average of $127.69.

Hedge Funds Weigh In On Neurocrine Biosciences

Several large investors have recently made changes to their positions in the business. Vestal Point Capital LP bought a new stake in Neurocrine Biosciences during the 4th quarter valued at approximately $105,408,000. Los Angeles Capital Management LLC lifted its stake in Neurocrine Biosciences by 66.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after purchasing an additional 364,986 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Neurocrine Biosciences by 120.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company’s stock valued at $65,761,000 after purchasing an additional 319,564 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Neurocrine Biosciences by 73.0% during the 3rd quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock valued at $73,045,000 after purchasing an additional 273,952 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Neurocrine Biosciences during the fourth quarter valued at about $35,731,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares of the company’s stock, valued at approximately $3,909,454.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total transaction of $380,847.83. Following the transaction, the chief executive officer now owns 502,188 shares in the company, valued at approximately $70,652,829.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard F. Pops sold 15,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the sale, the director now owns 29,512 shares of the company’s stock, valued at approximately $3,909,454.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 186,994 shares of company stock valued at $25,806,409. Company insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.